## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.5% below STRENGTH zone (4.0-10.0%); PEG 1.75 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($241.18)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. The Truth About Steris plc: Quiet Healthcare Giant or Next Big Stock Glow-Up?**
- Source: AD HOC NEWS | 20260101T070843 | Bullish | Relevance: 100%
- Steris plc is presented as an unassuming but critical player in the healthcare sector, specializing in sterilization and infection control. The article explores whether this "boring-but-profitable" stock is a worthwhile long-term investment, highlighting its stable business model, consistent financial performance, and strong market positioning compared to competitors. It suggests Steris is a "cop" for serious, risk-aware investors seeking stable healthcare exposure rather than volatile, short-term gains.

**2. The Truth About Steris plc: Quiet Healthcare Giant or Next Big Stock Glow-Up?**
- Source: AD HOC NEWS | 20260101T070837 | Bullish | Relevance: 100%
- Steris plc is presented as an under-the-radar healthcare giant focused on sterilization and infection control, a critical but unflashy sector. The article examines its business model, financial performance, and competitive landscape, concluding it's a solid, low-drama investment for long-term, risk-aware portfolios rather than a speculative, high-growth stock. It highlights Steris's stable cash flows and essential role in the healthcare system as reasons for its appeal to serious investors.

**3. STERIS plc $STE Shares Sold by Pacer Advisors Inc.**
- Source: MarketBeat | 20260101T105243 | Neutral | Relevance: 100%
- Pacer Advisors Inc. significantly reduced its stake in STERIS plc (NYSE:STE) by 41.7% in the third quarter, selling 5,950 shares and holding 8,320 shares valued at $2,059,000. Despite this, other hedge funds like Norges Bank and Orbis Allan Gray Ltd increased their positions, indicating mixed institutional investor sentiment. STERIS reported strong earnings, beating analyst estimates, and has a "Moderate Buy" average rating from Wall Street analysts.

**4. STERIS plc $STE Stock Position Lifted by Fenimore Asset Management Inc**
- Source: MarketBeat | 20260101T101643 | Bullish | Relevance: 100%
- Fenimore Asset Management Inc. increased its stake in STERIS plc (NYSE:STE) by 4.1% during the third quarter, making it their 25th largest holding, valued at approximately $80.41 million. The company recently reported strong quarterly earnings, beating analyst estimates, and provided positive guidance for fiscal year 2026. This increase in institutional ownership comes despite recent insider selling by some company executives.

**5. Steris plc stock: Quiet chart, steady climb â€“ and a healthcare compounder hiding in plain sight**
- Source: AD HOC NEWS | 20260101T030907 | Bullish | Relevance: 100%
- Steris plc (STERIS) has shown steady growth on its charts despite broader healthcare volatility, nearing its record high. Analysts maintain bullish targets for the low-drama sterilization specialist, highlighting resilient demand, expanding margins, and stable share price appreciation. The company's performance is driven by consistent demand for sterilization and decontamination solutions, reflecting its role as a reliable healthcare compounder.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.75 elevated, pricing in significant growth expectations. Forward P/E 22.5x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.6B |
| Beta | 1.01 |
| 52W Range | $203.35 - $268.60 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.75 |
| Forward P/E | 22.5 |
| Current P/E | 24.5 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -1.5% (minimal 5-day change). Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.53% (CS: 23) | Neutral |
| RSI_14 | 38.9 | Neutral |
| MACD Histogram | -0.50 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.983x | Below |
| vs SMA200 | 1.040x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $250.04
- **Stop Loss:** $241.18 (3.5% risk)
- **Target:** $258.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 162
- **Position Value:** $40,506.48
- **Portfolio %:** 40.51%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*